<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">DIJ</journal-id><journal-id journal-id-type="hwp">spdij</journal-id><journal-title>Therapeutic Innovation &amp; Regulatory Science</journal-title><issn pub-type="ppub">2168-4790</issn><issn pub-type="epub">2164-9200</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1177/2168479013486658</article-id><article-id pub-id-type="publisher-id">10.1177_2168479013486658</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials</subject></subj-group></article-categories><title-group><article-title>Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Wachtlin</surname><given-names>Daniel</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff1-2168479013486658">1</xref><xref ref-type="corresp" rid="corresp1-2168479013486658"/></contrib><contrib contrib-type="author"><name><surname>Kieser</surname><given-names>Meinhard</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2-2168479013486658">2</xref></contrib></contrib-group><aff id="aff1-2168479013486658"><label>1</label>Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz, Germany</aff><aff id="aff2-2168479013486658"><label>2</label>Institute of Medical Biometry and Informatics (IMBI), Heidelberg, Germany</aff><author-notes><corresp id="corresp1-2168479013486658">Daniel Wachtlin, Biometrics Department, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz, Langenbeckstr. 2, 55131 Mainz, Germany. Email: <email>wachtlin@izks-mainz.de</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>7</month><year>2013</year></pub-date><volume>47</volume><issue>4</issue><fpage>460</fpage><lpage>467</lpage><history><date date-type="received"><day>5</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>© The Author(s) 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder content-type="other">Drug Information Association</copyright-holder></permissions><abstract><p>In clinical trials in which outcomes are measured repeatedly during the follow-up phase, data analysis is frequently performed using generalized estimating equations (GEEs). Sample size calculation is then especially challenging since in addition to the treatment effect, the intrasubject correlation and the variability of the model error term have to be specified. In this article, the authors investigated by Monte Carlo simulations whether a blinded midcourse estimation of these quantities in an internal pilot study design is feasible in such trials and whether nominal type I and type II error rates are preserved when the estimates are used for sample size recalculation. The actual type I error rates of the blinded sample size recalculation procedure turned out to agree well with the nominal levels. Furthermore, the simulated power was observed to be near the target value as long as the sample size of the internal pilot study was sufficiently high and the bound effects induced by the range of the correlation were limited. The proposed procedure is a helpful tool to achieve robustness of the power with respect to initial misspecifications in the planning stage in clinical trials analyzed by GEE.</p></abstract><kwd-group><kwd>sample size calculation</kwd><kwd>internal pilot study</kwd><kwd>generalized estimating equations</kwd><kwd>missing data</kwd><kwd>longitudinal clinical trials</kwd></kwd-group></article-meta></front><body><sec id="section1-2168479013486658"><title>Introduction</title><p>In the planning stage of a clinical trial, the required sample size has to be calculated, requiring assumptions about various parameters. This is particularly demanding in longitudinal clinical trials, where among other things the correlation between observations taken from the same subject has to be taken into account, thus making sample size calculation more complex. Apart from generalized linear mixed models (GLMMs), generalized estimating equations (GEEs) first introduced by Liang and Zeger<sup><xref ref-type="bibr" rid="bibr1-2168479013486658">1</xref></sup> are an adequate approach for analyzing longitudinal data.<sup><xref ref-type="bibr" rid="bibr2-2168479013486658">2</xref></sup> Various methods for sample size estimation for GEE analyses have been discussed in the literature.<sup><xref ref-type="bibr" rid="bibr3-2168479013486658">3</xref><xref ref-type="bibr" rid="bibr4-2168479013486658"/>–<xref ref-type="bibr" rid="bibr5-2168479013486658">5</xref></sup> Jung and Ahn<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref></sup> proposed a closed formula for studies designed to test for between-group differences in the change of an outcome variable by applying GEE analyses. Besides the assumed mean and variance of the treatment effect and the specified type I and type II error probabilities, their formula also includes parameters representing the strength and structure of intrasubject correlation and the amount of missing data. The formula assumes large sample sizes and data missing completely at random (MCAR).<sup><xref ref-type="bibr" rid="bibr7-2168479013486658">7</xref></sup> Jung and Ahn<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref></sup> and Zhang and Ahn<sup><xref ref-type="bibr" rid="bibr8-2168479013486658">8</xref></sup> demonstrated strong effects of the within-subject association of repeated measurements and the amount of missing data on the required sample size. Zhang and Ahn<sup><xref ref-type="bibr" rid="bibr8-2168479013486658">8</xref></sup> further showed by simulation studies that the achieved power is close to the desired value even for small sample sizes.</p><p>As it is usually difficult to give a correct guess of the parameters necessary to calculate the required sample size, these results<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref>,<xref ref-type="bibr" rid="bibr8-2168479013486658">8</xref></sup> raise the question whether and how erroneous initial assumptions about parameters may be corrected during the ongoing trial. One way to address this issue is the design with internal pilot study (IPS), in which initial assumptions are reevaluated during the ongoing trial and the sample size is recalculated accordingly. The characteristics of the IPS design have been investigated for different types of outcomes, study designs, and evaluation methods.<sup><xref ref-type="bibr" rid="bibr9-2168479013486658">9</xref><xref ref-type="bibr" rid="bibr10-2168479013486658"/><xref ref-type="bibr" rid="bibr11-2168479013486658"/><xref ref-type="bibr" rid="bibr12-2168479013486658"/><xref ref-type="bibr" rid="bibr13-2168479013486658"/><xref ref-type="bibr" rid="bibr14-2168479013486658"/>–<xref ref-type="bibr" rid="bibr15-2168479013486658">15</xref></sup> To maintain the integrity of a study, IPS designs are especially appealing when data do not require unblinding for reestimating the parameters. In a recent review on sample size reestimation,<sup><xref ref-type="bibr" rid="bibr16-2168479013486658">16</xref></sup> the authors state that “it is usually preferable for SSR [sample size reestimation] based on updated information about nuisance parameters to be performed on a blinded basis.” This view is shared by regulatory guidelines.<sup><xref ref-type="bibr" rid="bibr17-2168479013486658">17</xref><xref ref-type="bibr" rid="bibr18-2168479013486658"/>–<xref ref-type="bibr" rid="bibr19-2168479013486658">19</xref></sup></p><p>The main interest of longitudinal clinical trials analyzed by GEE is usually the comparison of outcome changes between treatment groups. Of course, reestimating the slope parameters for the treatment groups would require breaking the blind for all study participants. In contrast, reestimation of nuisance parameters such as the unexplained variability, the within-subject correlation, and the amount of missing data does not require unblinding as long as no major differences between treatment groups are expected for these parameters. A blinded recalculation of these parameters may thus achieve more robustness of the resulting power against potential misspecifications made in the planning phase. However, for the following reasons there is no guarantee that sample size recalculation is feasible in this setting and that the chosen procedure preserves the nominal type I and type II error rates. First, the recalculated sample size is no longer fixed but random and will follow a distribution depending on the true parameter values and the (random) data observed within the internal pilot study. Second, updated estimates strongly depend on the chosen recalculation procedure. Especially for the complex estimation of intrasubject correlation requiring simultaneous estimation of several parameters dependent on the chosen correlation model, the availability of appropriate estimates is not ensured a priori. Restrictions imposed by the sample size recalculation rule may cause further complications.</p><p>The objective of the research presented in this article was to investigate the feasibility and the statistical properties of a blinded sample size recalculation procedure based on the sample size formula proposed by Jung and Ahn.<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref></sup> Sample size was recalculated in an IPS design based on midcourse estimates of within-subject association, model error term variability, and the amount of missing data.</p></sec><sec id="section2-2168479013486658" sec-type="methods"><title>Methods</title><sec id="section3-2168479013486658"><title>Statistical Model</title><p>The proposed sample size recalculation procedure was investigated for the following longitudinal data model:<disp-formula id="disp-formula1-2168479013486658"><mml:math id="mml-disp1-2168479013486658"><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mrow><mml:mrow><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mrow><mml:mrow><mml:mn mathvariant="normal">2</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:msub><mml:mi>r</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mrow><mml:mrow><mml:mn mathvariant="normal">3</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:mi>j</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mrow><mml:mrow><mml:mn mathvariant="normal">4</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:msub><mml:mi>r</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>j</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mi mathvariant="italic">ϵ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">,</mml:mo></mml:math><graphic alternate-form-of="disp-formula1-2168479013486658" xlink:href="10.1177_2168479013486658-eq1.tif"/></disp-formula></p><p>where <italic>y<sub>ij</sub></italic> is a continuous outcome variable measured for subject <italic>i</italic> at time <italic>j</italic>, and <italic>r<sub>i</sub></italic> indicates the treatment that the subject received (<italic>r<sub>i</sub></italic> = 0: control treatment;<italic> r<sub>i</sub></italic> = 1: experimental treatment). Within the introduced linear model, <italic>β</italic><sub>1</sub> is the intercept for a subject receiving the control treatment, and <italic>β</italic><sub>2</sub> is the true difference of intercepts between the experimental treatment group and the control group. The variable <italic>β</italic><sub>3</sub> is the true slope parameter in the control group, and <italic>β</italic><sub>4</sub> its difference to the experimental group; <italic>β</italic><sub>4</sub> thus reflects the difference of treatment effects and is the parameter of principal interest. The variable <italic>∊<sub>ij</sub></italic> denotes the unexplained variability for subject <italic>i</italic> at time <italic>j </italic>and is assumed to be normally distributed with expectation zero and variance <italic>σ</italic><sup>2</sup>. Fixed and equal measurement times <italic>j</italic> = 1, 2, …, <italic>K</italic> in both treatment groups were investigated in all simulation scenarios presented in this paper.</p></sec><sec id="section4-2168479013486658"><title>Sample Size Calculation</title><p>In our simulation studies, the total sample size <italic>n</italic> was calculated according to the approximation formula of Jung and Ahn,<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref></sup> which was developed for studies designed to detect a difference between slope parameters of 2 treatment groups when analysis is planned using GEE:<disp-formula id="disp-formula2-2168479013486658"><mml:math id="mml-disp2-2168479013486658"><mml:mi>n</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mi mathvariant="italic">σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:msubsup><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mi mathvariant="italic">α</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mi mathvariant="italic">γ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msubsup><mml:mi mathvariant="italic">β</mml:mi><mml:mn>4</mml:mn><mml:mrow><mml:mrow><mml:mo mathvariant="normal" stretchy="false">∗</mml:mo></mml:mrow></mml:mrow></mml:msubsup></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:msubsup><mml:mi mathvariant="italic">μ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:mi>t</mml:mi><mml:mn>4</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow><mml:mo stretchy="false">,</mml:mo></mml:math><graphic alternate-form-of="disp-formula2-2168479013486658" xlink:href="10.1177_2168479013486658-eq2.tif"/></disp-formula></p><p>where<italic> σ</italic><sup>2</sup> denotes the variance of the error term, that is, <italic>σ</italic><sup>2</sup> = <italic>Var</italic>(<italic>∊<sub>ij</sub></italic>); <inline-formula id="inline-formula1-2168479013486658"><mml:math id="mml-inline1-2168479013486658"><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mi mathvariant="italic">α</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula id="inline-formula2-2168479013486658"><mml:math id="mml-inline2-2168479013486658"><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mi mathvariant="italic">γ</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> identify the <inline-formula id="inline-formula3-2168479013486658"><mml:math id="mml-inline3-2168479013486658"><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mi mathvariant="italic">α</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:math></inline-formula> and 1 – <italic>γ</italic> quantiles of the standard normal distribution; and <italic>α</italic> and <italic>γ</italic> are the specified type I and type II error rates. The value of <italic>β</italic><sub>4</sub> under the alternative hypothesis is represented as <inline-formula id="inline-formula4-2168479013486658"><mml:math id="mml-inline4-2168479013486658"><mml:msubsup><mml:mi mathvariant="italic">β</mml:mi><mml:mn>4</mml:mn><mml:mo stretchy="false">∗</mml:mo></mml:msubsup></mml:math></inline-formula>. The parameter <inline-formula id="inline-formula5-2168479013486658"><mml:math id="mml-inline5-2168479013486658"><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo accent="true" stretchy="false">ˉ</mml:mo></mml:mover><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo accent="true" stretchy="false">ˉ</mml:mo></mml:mover></mml:mrow></mml:mfenced></mml:math></inline-formula>, <inline-formula id="inline-formula6-2168479013486658"><mml:math id="mml-inline6-2168479013486658"><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo accent="true" stretchy="false">ˉ</mml:mo></mml:mover><mml:mo stretchy="false">=</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac></mml:mrow><mml:munderover><mml:mrow><mml:mo stretchy="false">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:msub><mml:mi>r</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> denotes the variance of the treatment group indicator. Furthermore, <inline-formula id="inline-formula7-2168479013486658"><mml:math id="mml-inline7-2168479013486658"><mml:msubsup><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:munderover><mml:mrow><mml:mo stretchy="false">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:munderover><mml:mrow><mml:mo stretchy="false">∑</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="italic">ρ</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mi>j</mml:mi><mml:mo stretchy="false">−</mml:mo><mml:msub><mml:mi mathvariant="italic">μ</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfenced><mml:mfenced close=")" open="("><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">−</mml:mo><mml:msub><mml:mi mathvariant="italic">μ</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula>, <inline-formula id="inline-formula8-2168479013486658"><mml:math id="mml-inline8-2168479013486658"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">δ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="italic">δ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>, <inline-formula id="inline-formula9-2168479013486658"><mml:math id="mml-inline9-2168479013486658"><mml:msub><mml:mi mathvariant="italic">ρ</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">ϵ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">,</mml:mo><mml:msub><mml:mi mathvariant="italic">ϵ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>, <inline-formula id="inline-formula10-2168479013486658"><mml:math id="mml-inline10-2168479013486658"><mml:msub><mml:mi mathvariant="italic">μ</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:msubsup><mml:mi mathvariant="italic">μ</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mo stretchy="false">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:munderover><mml:mrow><mml:mo stretchy="false">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>.</mml:mo><mml:msup><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo stretchy="false">,</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">,</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula>, <inline-formula id="inline-formula11-2168479013486658"><mml:math id="mml-inline11-2168479013486658"><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">δ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>,<inline-formula id="inline-formula12-2168479013486658"><mml:math id="mml-inline12-2168479013486658"><mml:mtext> </mml:mtext><mml:msub><mml:mi mathvariant="italic">μ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:munderover><mml:mrow><mml:mo stretchy="false">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula>, and <inline-formula id="inline-formula13-2168479013486658"><mml:math id="mml-inline13-2168479013486658"><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:msub><mml:mi mathvariant="italic">μ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">−</mml:mo><mml:msubsup><mml:mi mathvariant="italic">μ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula>. The parameter <italic>δ<sub>ij</sub></italic> is an indicator variable showing whether the outcome was observed (<italic>δ<sub>ij</sub></italic> = 1) or not (<italic>δ<sub>ij</sub></italic> = 0) for subject <italic>i</italic> and measurement time <italic>j</italic>.</p><p>As a first step within the simulation study, several parameter values had to be defined to determine the number of patients required in the fixed sample size design. The 2-sided significance level <italic>α</italic> was set to 5%, the desired power 1 – <italic>γ</italic> to 80%, and the number of measurement times <italic>K</italic> to 6; balanced designs were considered in all simulation scenarios presented in this paper, that is, <inline-formula id="inline-formula14-2168479013486658"><mml:math id="mml-inline14-2168479013486658"><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo accent="true" stretchy="false">ˉ</mml:mo></mml:mover><mml:mo stretchy="false">=</mml:mo><mml:mn>0.5</mml:mn></mml:math></inline-formula>. Furthermore, <italic>h</italic> was defined as the risk of dropout at every post-baseline visit <italic>j </italic>≥ 2. This risk did not differ between treatment groups, subjects, and measurement times in the investigated scenarios. Note that within the simulation study, the respective true values of <italic>h</italic> were known. The parameter <italic>p<sub>j</sub></italic>, the fractions of observed data at measurement time <italic>j</italic>, were calculated based on this risk of dropout <italic>h</italic> as <italic>p<sub>j</sub></italic> = (1 – <italic>h</italic>)<italic><sup>j</sup></italic><sup>–1</sup>, <italic>j</italic> = 1, 2, …, 6. Analogously, the fractions of patients with observed data at both measurement times <italic>j</italic> and <italic>j′</italic> were calculated as <inline-formula id="inline-formula15-2168479013486658"><mml:math id="mml-inline15-2168479013486658"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced><mml:mrow><mml:mi>j</mml:mi><mml:mo stretchy="false">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mrow/></mml:mrow><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:msup><mml:mi>j</mml:mi><mml:msup><mml:mi/><mml:mo>′</mml:mo></mml:msup></mml:msup><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">,</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">,</mml:mo><mml:mo stretchy="false">…</mml:mo><mml:mo stretchy="false">,</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="false">,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">≠</mml:mo><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>.</mml:mo><mml:mrow><mml:mrow/></mml:mrow></mml:math></inline-formula>Within-subject association of repeated measurements according to the damped exponential family of correlation structures introduced by Munoz et al<sup><xref ref-type="bibr" rid="bibr20-2168479013486658">20</xref></sup> was assumed in the simulation study, which is in line with the investigations of Zhang and Ahn.<sup><xref ref-type="bibr" rid="bibr8-2168479013486658">8</xref></sup> In the damped exponential family of correlation structures, 2 parameters are used to model the correlation matrix: <italic>ρ</italic> is defined as the correlation between 2 measurements taken from the same subject with a distance of 1 time unit, and <italic>θ</italic> denotes the decrease in correlation with increasing distance between measurements. Formally, the correlation between 2 observations with a distance of <italic>t</italic> units is defined as <inline-formula id="inline-formula16-2168479013486658"><mml:math id="mml-inline16-2168479013486658"><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">,</mml:mo><mml:mrow><mml:mrow/></mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo stretchy="false">=</mml:mo><mml:msup><mml:mi mathvariant="italic">ρ</mml:mi><mml:mrow><mml:msup><mml:mi>t</mml:mi><mml:mi mathvariant="italic">θ</mml:mi></mml:msup></mml:mrow></mml:msup></mml:math></inline-formula>. Compound symmetry (CS; <italic>θ</italic> = 0) and continuous autocorrelation of order 1 (AR(1); <italic>θ </italic>= 1) reflect the extreme cases covered by this model. Furthermore, initial values of the variance of measurement error <italic>σ</italic><sup>2</sup> and the difference of slopes between treatment groups <inline-formula id="inline-formula17-2168479013486658"><mml:math id="mml-inline17-2168479013486658"><mml:msubsup><mml:mi mathvariant="italic">β</mml:mi><mml:mn>4</mml:mn><mml:mo stretchy="false">∗</mml:mo></mml:msubsup></mml:math></inline-formula> were needed. Based on all these parameter values, the approximate sample size required within the fixed design was calculated according to the closed formula of Jung and Ahn.<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref></sup></p></sec><sec id="section5-2168479013486658"><title>Blinded Estimation of Nuisance Parameters and Sample Size Recalculation</title><p>The size of the internal pilot study was determined as a fraction π, 0 &lt; π &lt; 1 of the number of patients required in the fixed sample size design.</p><p>Next, data for the internal pilot study were generated based on the parameter values of the considered scenarios. The parameters <italic>ρ</italic> and <italic>θ</italic> representing the intrasubject correlation and the variance of measurement error <italic>σ</italic><sup>2</sup> were simultaneously reestimated in a blinded manner. A nonlinear model was applied that minimized the unweighted sum of absolute differences between the elements of the model-based covariance matrix and those of the empirical covariance matrix based on the pooled data of the patients included in the internal pilot study. Model-based restrictions for parameters (0 ≤ <italic>ρ</italic>, <italic>θ </italic>≤ 1, <italic>σ</italic><sup>2</sup> ≥ 0) were used, and the starting values for the estimation algorithm were set to <italic>ρ </italic>= 1, <italic>θ</italic> = 1, <italic>σ</italic><sup>2</sup> = 1. The risk of dropout <italic>h</italic> was reestimated based on the fraction of observed data at the last measurement time <italic>j </italic>= 6 for those subjects included into the internal pilot study, <inline-formula id="inline-formula18-2168479013486658"><mml:math id="mml-inline18-2168479013486658"><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mrow><mml:mn>6</mml:mn><mml:mo stretchy="false">,</mml:mo><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (ie, <inline-formula id="inline-formula19-2168479013486658"><mml:math id="mml-inline19-2168479013486658"><mml:msub><mml:mover accent="true"><mml:mi>h</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">−</mml:mo><mml:mroot><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mrow><mml:mn>6</mml:mn><mml:mo stretchy="false">,</mml:mo><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mn>5</mml:mn></mml:mroot></mml:math></inline-formula>); the subscript <italic>IPS</italic> indicates that estimates are based on internal pilot study data. It was expected that estimation based on data at the last measurement time <italic>j</italic> = 6 would be most robust against sampling variation, since information about dropout rates at all measurement times is used for estimation by this approach.</p><p>The sample size was recalculated by using the parameter estimates obtained from the internal pilot study in the formula of Jung and Ahn<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref></sup> given above. If the recalculated sample size exceeded the size of the internal pilot study, data for the additional patients were simulated. An unrestricted internal pilot study design according to Birkett and Day<sup><xref ref-type="bibr" rid="bibr21-2168479013486658">21</xref></sup> was chosen, meaning that no lower and upper sample size limit was defined. Implicitly, the size of the internal pilot study defined the lowest possible sample size.</p></sec><sec id="section6-2168479013486658"><title>Data Analysis</title><p>Analysis was performed by GEE with all data of a simulation run. Following the investigations of Mancl and Leroux<sup><xref ref-type="bibr" rid="bibr22-2168479013486658">22</xref></sup> and Ziegler and Vens,<sup><xref ref-type="bibr" rid="bibr23-2168479013486658">23</xref></sup> an independent working correlation matrix was chosen. In scenarios with missing data, weighted estimating equations<sup><xref ref-type="bibr" rid="bibr24-2168479013486658">24</xref></sup> were applied for the analysis. Due to the dropout pattern considered in the simulations, the inverse probability weighting method produced weights that were different between but not within measurement times. Within the estimated model, it was tested whether slope differences were significantly different from zero whereby tests were performed at a 1-sided significance level of 2.5%. For each simulation scenario, 10,000 simulation runs were performed under the null hypothesis <italic>β</italic><sub>4</sub> = 0 and under the alternative hypothesis <inline-formula id="inline-formula20-2168479013486658"><mml:math id="mml-inline20-2168479013486658"><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo stretchy="false">=</mml:mo><mml:msubsup><mml:mi mathvariant="italic">β</mml:mi><mml:mn>4</mml:mn><mml:mo stretchy="false">∗</mml:mo></mml:msubsup></mml:math></inline-formula>. For simulations under the null hypothesis, the corresponding sample size under the alternative hypothesis was used. The empirical type I and type II error rates were calculated as the number of rejections divided by the number of simulation runs. The steps of the simulation study are illustrated in <xref ref-type="fig" rid="fig1-2168479013486658">Figure 1</xref>. Note that applying the proposed recalculation procedure in practice requires initial estimates of the parameters based on previous studies or published data. Assumptions like the constant risk of dropout and intrasubject correlation according to the damped exponential family of correlation structures<sup><xref ref-type="bibr" rid="bibr20-2168479013486658">20</xref></sup> do not necessarily need to be maintained during this initial estimation.</p><fig id="fig1-2168479013486658" position="float"><label>Figure 1.</label><caption><p>Simulation Study.</p></caption><graphic xlink:href="10.1177_2168479013486658-fig1.tif"/></fig></sec><sec id="section7-2168479013486658"><title>Simulation Scenarios</title><p>The following scenarios were investigated in the simulation study. Scenarios 1 to 8 reflect situations without dropouts, that is, <italic>h</italic> = 0. In scenario 1, a moderate correlation <italic>ρ</italic> = 0.25, a decrease parameter <italic>θ</italic> = 0.5, and a variance of the measurement error of <italic>σ</italic><sup>2</sup> = 1 were considered. The internal pilot study comprised half of the sample size required for the fixed sample size design (<italic>π</italic> = 0.5). Scenarios 2 and 3 were slight modifications of scenario 1 in the sense that the relative size of the internal pilot study was smaller (<italic>π </italic>= 0.2) or larger (<italic>π </italic>= 0.8). In these scenarios, the influence of the size of the internal pilot study on the updated parameter estimates as well as on type I and type II error probabilities was investigated. In scenarios 4 to 8, alternative values for the parameters <italic>ρ</italic>, <italic>θ</italic>, and <italic>σ</italic><sup>2</sup> were considered in order to evaluate whether the true values of the parameters affect the quality of parameter estimation. Scenarios 9 to 12 revisit scenarios 2 and 3 but include the dropout rates <italic>h</italic> = 1% or <italic>h</italic> = 5%, respectively. Details of all scenarios are summarized in <xref ref-type="table" rid="table1-2168479013486658">Table 1</xref>.</p><table-wrap id="table1-2168479013486658" position="float"><label>Table 1.</label><caption><p>Simulation scenarios.</p></caption><graphic alternate-form-of="table1-2168479013486658" xlink:href="10.1177_2168479013486658-table1.tif"/><table><thead><tr><th>Scenario</th><th>ρ</th><th>θ</th><th>σ<sup><xref ref-type="bibr" rid="bibr2-2168479013486658">2</xref></sup></th><th><italic>h</italic></th><th>π</th><th>n</th><th>n<sub>IPS</sub></th></tr></thead><tbody><tr><td> 1</td><td>0.25</td><td>0.5</td><td>1</td><td>0.00</td><td>0.5</td><td>203</td><td>102</td></tr><tr><td> 2</td><td>0.25</td><td>0.5</td><td>1</td><td>0.00</td><td>0.2</td><td>203</td><td>41</td></tr><tr><td> 3</td><td>0.25</td><td>0.5</td><td>1</td><td>0.00</td><td>0.8</td><td>203</td><td>162</td></tr><tr><td> 4</td><td>0.7</td><td>0.1</td><td>1</td><td>0.00</td><td>0.5</td><td>67</td><td>34</td></tr><tr><td> 5</td><td>0.7</td><td>1</td><td>1</td><td>0.00</td><td>0.5</td><td>223</td><td>112</td></tr><tr><td> 6</td><td>0.25</td><td>0.5</td><td>5</td><td>0.00</td><td>0.5</td><td>1015</td><td>508</td></tr><tr><td> 7</td><td>0.1</td><td>0.1</td><td>1</td><td>0.00</td><td>0.5</td><td>172</td><td>86</td></tr><tr><td> 8</td><td>0.1</td><td>0.9</td><td>1</td><td>0.00</td><td>0.5</td><td>197</td><td>98</td></tr><tr><td> 9</td><td>0.25</td><td>0.5</td><td>1</td><td>0.01</td><td>0.2</td><td>208</td><td>42</td></tr><tr><td>10</td><td>0.25</td><td>0.5</td><td>1</td><td>0.05</td><td>0.2</td><td>231</td><td>46</td></tr><tr><td>11</td><td>0.25</td><td>0.5</td><td>1</td><td>0.01</td><td>0.8</td><td>208</td><td>166</td></tr><tr><td>12</td><td>0.25</td><td>0.5</td><td>1</td><td>0.05</td><td>0.8</td><td>231</td><td>185</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-2168479013486658"><p>Symbols explained in the text except for n<sub>IPS</sub> = sample size of internal pilot study.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="section8-2168479013486658"><title>Results</title><p>At first, the results for reestimating <italic>ρ</italic>, <italic>θ</italic>, and <italic>σ</italic><sup>2</sup> are presented. Only the results of simulations under the alternative hypothesis are shown. Estimation of <italic>ρ</italic>, <italic>θ</italic>, and <italic>σ</italic><sup>2</sup> under the null hypothesis turned out to be on average slightly closer to the corresponding true values. <xref ref-type="fig" rid="fig2-2168479013486658">Figure 2</xref> depicts the distribution of reestimated <italic>ρ</italic> and <italic>θ </italic>for the scenarios 2, 3, 5 and 7.</p><fig id="fig2-2168479013486658" position="float"><label>Figure 2.</label><caption><p>Results for reestimating <italic>ρ</italic> and <italic>θ</italic>. The dashed vertical lines denote the corresponding true value of <inline-formula id="inline-formula21-2168479013486658"><mml:math id="mml-inline21-2168479013486658"><mml:mi mathvariant="italic">ρ</mml:mi></mml:math></inline-formula> (left) or <inline-formula id="inline-formula22-2168479013486658"><mml:math id="mml-inline22-2168479013486658"><mml:mi mathvariant="italic">θ</mml:mi></mml:math></inline-formula> (right), respectively.</p></caption><graphic xlink:href="10.1177_2168479013486658-fig2.tif"/></fig><p>The parameter <italic>ρ</italic> is on average estimated near the true values, whereby estimation is more precise in scenarios with a high number of patients included in the IPS. Distributions are slightly skewed whenever the true values are near the limits of the range of possible parameter values. </p><p>Reestimation of <italic>θ</italic> turns out to be less precise. In scenario 2 with only 41 patients included in the IPS, the estimated value of <italic>θ</italic> is nearly uniformly distributed over the range of valid values. In approximately 15.1% of the simulation replications, the extreme values 0 or 1 were obtained as estimates whereby estimates at the upper bound were more frequent (12.1% vs 3.0%). The latter holds true for scenario 3 as well, although variability is considerably reduced given the higher number of subjects included in the IPS. The upper bound is still obtained as an estimate in 0.7% of the simulation replications. This phenomenon can be explained as follows: In the simulated random samples, intrasubject correlations depart from their theoretical probability distributions because of sampling variation. In particular, single cells of the empirical correlation matrices may become negative. However, such values are not valid in the damped exponential family of correlation structures.<sup><xref ref-type="bibr" rid="bibr20-2168479013486658">20</xref></sup> In the considered correlation model <inline-formula id="inline-formula23-2168479013486658"><mml:math id="mml-inline23-2168479013486658"><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">,</mml:mo><mml:mrow><mml:mrow/></mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo stretchy="false">=</mml:mo><mml:msup><mml:mi mathvariant="italic">ρ</mml:mi><mml:mrow><mml:msup><mml:mi>t</mml:mi><mml:mi mathvariant="italic">θ</mml:mi></mml:msup></mml:mrow></mml:msup></mml:math></inline-formula>, <italic>θ</italic> indicates the extent of decay of correlation with increasing distance between measurements with a maximum decay at <inline-formula id="inline-formula24-2168479013486658"><mml:math id="mml-inline24-2168479013486658"><mml:mi mathvariant="italic">θ</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula>. Thus, the value <inline-formula id="inline-formula25-2168479013486658"><mml:math id="mml-inline25-2168479013486658"><mml:mi mathvariant="italic">θ</mml:mi><mml:mo stretchy="false">=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> may be a straightforward estimate when the underlying empirical correlation matrix contains negative values.</p><p>In scenarios 5 and 7, the true values for <italic>θ</italic> are near or equal to the model-based bounds, thus forcing the distribution of the reestimated values into a skewed shape. Mean estimates of <italic>σ</italic><sup>2</sup> are close to the true values in all scenarios. Estimates are more precise whenever the sample size of the IPS is sufficiently high. This can be seen by comparing the results for the scenarios 2 and 3 in <xref ref-type="fig" rid="fig3-2168479013486658">Figure 3</xref>.</p><fig id="fig3-2168479013486658" position="float"><label>Figure 3.</label><caption><p>Results for reestimating <inline-formula id="inline-formula26-2168479013486658"><mml:math id="mml-inline26-2168479013486658"><mml:msup><mml:mi mathvariant="italic">σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> and the sample size. The dashed vertical lines denote the corresponding true value of <inline-formula id="inline-formula27-2168479013486658"><mml:math id="mml-inline27-2168479013486658"><mml:msup><mml:mi mathvariant="italic">σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> (left) or the sample size required in the fixed sample size design (right).</p></caption><graphic xlink:href="10.1177_2168479013486658-fig3.tif"/></fig><p>The sample size distributions for scenarios 2, 3, 5, and 7 resulting from the updated estimates of <italic>ρ</italic>, <italic>θ</italic>, and <italic>σ</italic><sup>2</sup> are shown in <xref ref-type="fig" rid="fig3-2168479013486658">Figure 3</xref>. Remember that for these 4 simulation scenarios it is assumed that no missing data occur. Sample size is on average well estimated by the recalculation procedure (mean reestimated sample size near the value required for the related fixed sample size design, symmetric distribution of estimates). Variability of estimates is highest in scenario 2 because of the low sample size of the IPS. The sample size distribution in scenario 7 is slightly right-skewed because of the more frequent overestimation of <italic>ρ</italic>. In simulations comprising an IPS, the mean sample size is higher than in the fixed sample size design, which is attributable to the mean overestimation of <italic>θ</italic>.</p><p>In <xref ref-type="table" rid="table2-2168479013486658">Table 2</xref>, we present the results for the major research questions: Does blinded sample size recalculation in studies analyzed with GEE achieve robustness in power, and does the procedure maintain the specified type I error rate? The simulated type I and type II error rates for the scenarios 1 to 12 are shown and the results for the fixed sample size design are presented for comparison. Note that for 10,000 simulation runs, the standard error for the 1-sided type I error rate amounts to 0.16% and for the power to 0.40%.</p><table-wrap id="table2-2168479013486658" position="float"><label>Table 2.</label><caption><p>Simulated type I error rate α at power 1 – γ for proposed sample size recalculation procedure.</p></caption><graphic alternate-form-of="table2-2168479013486658" xlink:href="10.1177_2168479013486658-table2.tif"/><table><thead><tr><th>Scenario</th><th>n</th><th>n<sub>IPS</sub></th><th>Mean (n<sub>recalc</sub>)</th><th>α<sub>fixed</sub></th><th>(1–γ)<sub>fixed</sub></th><th>α<sub>IPS</sub></th><th>(1–γ)<sub>IPS</sub></th></tr></thead><tbody><tr><td> 1</td><td>203</td><td>102</td><td>206.4</td><td>2.37</td><td>80.34</td><td>2.70</td><td>80.61</td></tr><tr><td> 2</td><td>203</td><td>41</td><td>203.5</td><td>2.87</td><td>80.42</td><td>2.56</td><td>79.20</td></tr><tr><td> 3</td><td>203</td><td>162</td><td>207.2</td><td>2.51</td><td>80.20</td><td>2.49</td><td>80.69</td></tr><tr><td> 4</td><td>67</td><td>34</td><td>76.2</td><td>2.73</td><td>79.93</td><td>3.19</td><td>82.66</td></tr><tr><td> 5</td><td>223</td><td>112</td><td>223.8</td><td>2.67</td><td>79.90</td><td>2.78</td><td>79.90</td></tr><tr><td> 6</td><td>1015</td><td>508</td><td>1017.9</td><td>2.54</td><td>80.36</td><td>2.38</td><td>79.88</td></tr><tr><td> 7</td><td>172</td><td>86</td><td>179.4</td><td>2.54</td><td>80.68</td><td>2.53</td><td>81.23</td></tr><tr><td> 8</td><td>197</td><td>98</td><td>198.9</td><td>2.55</td><td>80.15</td><td>2.54</td><td>79.49</td></tr><tr><td> 9</td><td>208</td><td>42</td><td>208.7</td><td>2.86</td><td>79.88</td><td>2.64</td><td>79.10</td></tr><tr><td>10</td><td>231</td><td>46</td><td>232.6</td><td>2.57</td><td>80.09</td><td>2.34</td><td>79.37</td></tr><tr><td>11</td><td>208</td><td>166</td><td>212.3</td><td>2.60</td><td>80.50</td><td>2.66</td><td>81.03</td></tr><tr><td>12</td><td>231</td><td>185</td><td>236.1</td><td>2.86</td><td>80.01</td><td>2.75</td><td>80.52</td></tr></tbody></table><table-wrap-foot><fn id="table-fn2-2168479013486658"><p>Fixed, fixed sample size design; IPS, internal pilot study design; recalc, recalculated.</p></fn></table-wrap-foot></table-wrap><p>The actual type I error rates for the fixed sample size design and the design with sample size recalculation are very similar and are close to nominal levels. The approximate sample size formula by Jung and Ahn<sup><xref ref-type="bibr" rid="bibr6-2168479013486658">6</xref></sup> is quite accurate as can be seen from the power values obtained for the fixed sample size design, which are near to the target value of 80%. Moreover, the IPS design with blinded sample size recalculation also provides powers close to the desired one. Note that a small overshoot in sample size is required for the IPS design to achieve the same power as in the fixed sample size design. This can be seen as the price to be paid for the option of sample size modification. It should further be mentioned that initial assumptions on the involved parameter values are only required to determine the size of the IPS. However, the achieved power does not depend heavily on the size of the IPS and therefore also does not depend heavily on the initial (possibly flawed) parameter estimates. Because of the smaller variability of the estimates, the power is slightly more accurately achieved for higher sample sizes of the internal pilot study. These results hold true both for the situation without and with dropouts.</p><sec id="section9-2168479013486658"><title>Clinical Trial Example</title><p>The GERAC migraine study was a randomized controlled 3-group trial investigating the efficacy of acupuncture for the prophylaxis of migraine.<sup><xref ref-type="bibr" rid="bibr25-2168479013486658">25</xref></sup> The primary end point was the change of the number of migraine days between the 4 weeks preceding the start of therapy and the 4 weeks preceding the 26-week follow-up visit. Let us assume for illustration of the above-described method that the primary end point should be evaluated with the GEE approach and that the trial was planned in an internal pilot study design with blinded reestimation of nuisance parameters after 100 randomized patients have completed the trial. For simplicity, we consider the 2-group comparison between verum acupuncture and sham acupuncture and assume a treatment difference in terms of slopes of <inline-formula id="inline-formula28-2168479013486658"><mml:math id="mml-inline28-2168479013486658"><mml:msubsup><mml:mi mathvariant="italic">β</mml:mi><mml:mn>4</mml:mn><mml:mo stretchy="false">∗</mml:mo></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:mn>0.33</mml:mn></mml:math></inline-formula>. Reliable guesses for the nuisance parameters involved in sample size calculation would have been hard to obtain in the planning phase. Based on the data of the first 100 randomized patients, the following parameter estimates were obtained: <inline-formula id="inline-formula29-2168479013486658"><mml:math id="mml-inline29-2168479013486658"><mml:mover accent="true"><mml:mi>h</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mo stretchy="false">=</mml:mo><mml:mn>1.7</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:math></inline-formula> (constant dropout rate), <inline-formula id="inline-formula30-2168479013486658"><mml:math id="mml-inline30-2168479013486658"><mml:mover accent="true"><mml:mi mathvariant="italic">ρ</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mo stretchy="false">=</mml:mo><mml:mn>0.28</mml:mn></mml:math></inline-formula>, <inline-formula id="inline-formula31-2168479013486658"><mml:math id="mml-inline31-2168479013486658"><mml:mover accent="true"><mml:mi mathvariant="italic">θ</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mo stretchy="false">=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> (according to the damped exponential family of correlation structures<sup><xref ref-type="bibr" rid="bibr20-2168479013486658">20</xref></sup>), and <inline-formula id="inline-formula32-2168479013486658"><mml:math id="mml-inline32-2168479013486658"><mml:msup><mml:mover accent="true"><mml:mi mathvariant="italic">σ</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">=</mml:mo><mml:mn>12.36</mml:mn></mml:math></inline-formula> (variance of the error term). Using these estimates, the following parameter values can be derived: <inline-formula id="inline-formula33-2168479013486658"><mml:math id="mml-inline33-2168479013486658"><mml:msubsup><mml:mover accent="true"><mml:mi>s</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:mn>3.51</mml:mn></mml:math></inline-formula>, <inline-formula id="inline-formula34-2168479013486658"><mml:math id="mml-inline34-2168479013486658"><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="italic">μ</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:mn>15.20</mml:mn></mml:math></inline-formula>, <inline-formula id="inline-formula35-2168479013486658"><mml:math id="mml-inline35-2168479013486658"><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="italic">σ</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:mn>0.25</mml:mn></mml:math></inline-formula>, and <inline-formula id="inline-formula36-2168479013486658"><mml:math id="mml-inline36-2168479013486658"><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="italic">σ</mml:mi><mml:mo accent="true" stretchy="false">ˆ</mml:mo></mml:mover><mml:mi>r</mml:mi><mml:mn>4</mml:mn></mml:msubsup><mml:mo stretchy="false">=</mml:mo><mml:mn>1.56</mml:mn></mml:math></inline-formula>. Using these values in the sample size formula leads to a patient number of 264 per group to achieve a power of 80% at a significance level of 5%.</p></sec></sec><sec id="section10-2168479013486658"><title>Discussion</title><p>In this article, feasibility and efficiency of the proposed sample size recalculation procedure based on blinded estimates of the intrasubject covariance and the dropout rate in an internal pilot study design were investigated with respect to the characteristics of the parameter estimates, the distribution of recalculated sample size, and the empirical type I and type II error rates. Updated estimates of the parameters <italic>ρ</italic> and <italic>σ</italic><sup>2</sup> seem to be unbiased as long as estimation is not close to the bounds of the range of valid parameter values. Reestimating <italic>θ</italic> is a more difficult task with a high variability and a considerable risk of bias. Of course, for all parameters, estimation becomes more efficient with an increasing number of patients included in the internal pilot study.</p><p>Despite some difficulties in estimating <italic>θ</italic>, the mean sample size resulting from updated parameter estimates is close to the sample size required in the fixed sample size design and differs only slightly in the presence of bound effects in parameter estimation. Again, the variability of sample size is low whenever the size of the IPS is large.</p><p>Type I error rates of the sample size recalculation procedure were mostly very near to the nominal values and were on average even closer to <italic>α</italic> than for the fixed sample size design. The power shows the desired robustness with respect to the planning assumptions: The target value of 80% power is met closely with increasing sample sizes of the IPS improving the accuracy.</p><p>Fixed and equal measurement times were investigated in the simulations presented in this article. Reestimation of the covariance parameters may be more challenging in settings where the measurement times differ between subjects since an increased overall number of measurement times and less information available at each measurement occasion may lead to less robust estimates of the covariance matrix.</p><p>To decide whether to apply a blinded sample size recalculation in a practical situation, initially estimated parameter values should be compared with extreme values within the range of values assumed to be realistic in this setting. By performing simulations for these extreme scenarios, we can anticipate bound effects and biased parameter reestimates. The algorithm by which <italic>ρ</italic>, <italic>θ</italic>, and <italic>σ</italic><sup>2</sup> are simultaneously estimated converged in all considered cases for the chosen starting values. Nevertheless, attention should be paid to the choice of starting values when simultaneously estimating intrasubject covariance parameters within the proposed sample size recalculation procedure. Convergence failure of the reestimation algorithm can be a considerable problem with a high impact on type I error and power of the procedure in some extreme cases.</p></sec></body><back><fn-group><fn fn-type="conflict" id="fn1-2168479013486658"><label>Declaration of Conflicting Interests</label><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure" id="fn2-2168479013486658"><label>Funding</label><p>The author(s) received no financial support for the research, authorship, and/or publication of this article. </p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2168479013486658"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>KY</given-names></name><name><surname>Zeger</surname><given-names>SL</given-names></name></person-group>. <article-title>Longitudinal data analysis using generalized linear models</article-title>. <source>Biometrika</source>.<year>1986</year>;<volume>73</volume>:<fpage>13</fpage>–<lpage>22</lpage>.</citation></ref><ref id="bibr2-2168479013486658"><label>2</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Fitzmaurice</surname><given-names>G</given-names></name><name><surname>Davidian</surname><given-names>M</given-names></name><name><surname>Verbeke</surname><given-names>G</given-names></name><name><surname>Molenberghs</surname><given-names>G</given-names></name></person-group>. <source>Longitudinal Data Analysis</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC</publisher-name>; <year>2008</year>.</citation></ref><ref id="bibr3-2168479013486658"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rochon</surname><given-names>J</given-names></name></person-group>. <article-title>Application of GEE procedures for sample size calculations in repeated measures experiments</article-title>. <source>Stat Med</source>. <year>1998</year>;<volume>17</volume>:<fpage>1643</fpage>–<lpage>1658</lpage>.</citation></ref><ref id="bibr4-2168479013486658"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahmen</surname><given-names>G</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name></person-group>. <article-title>Generalized estimating equation on controlled clinical trials: hypotheses testing</article-title>. <source>Biom J</source>. <year>2004</year>;<volume>46</volume>:<fpage>214</fpage>–<lpage>232</lpage>.</citation></ref><ref id="bibr5-2168479013486658"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahmen</surname><given-names>G</given-names></name><name><surname>Rochon</surname><given-names>J</given-names></name><name><surname>Koenig</surname><given-names>R</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name></person-group>. <article-title>Sample size calculations for controlled clinical trials using generalized estimating equations (GEE)</article-title>. <source>Methods Inf Med</source>. <year>2004</year>;<volume>43</volume>:<fpage>451</fpage>–<lpage>456</lpage>.</citation></ref><ref id="bibr6-2168479013486658"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>SH</given-names></name><name><surname>Ahn</surname><given-names>C</given-names></name></person-group>. <article-title>Sample size estimation for GEE method for comparing slopes in repeated measurements data</article-title>. <source>Stat Med</source>. <year>2003</year>;<volume>22</volume>:<fpage>1305</fpage>–<lpage>1315</lpage>.</citation></ref><ref id="bibr7-2168479013486658"><label>7</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Little</surname><given-names>RJA</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>. <source>Statistical Analysis With Missing Data</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Wiley</publisher-name>; <year>1987</year>.</citation></ref><ref id="bibr8-2168479013486658"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>C</given-names></name></person-group>. <article-title>Effects of correlation and missing data on sample size estimation in longitudinal clinical trials</article-title>. <source>Pharm Stat</source>. <year>2010</year>;<volume>9</volume>:<fpage>2</fpage>–<lpage>9</lpage>.</citation></ref><ref id="bibr9-2168479013486658"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wittes</surname><given-names>J</given-names></name><name><surname>Brittain</surname><given-names>E</given-names></name></person-group>. <article-title>The role of internal pilot studies in increasing efficiency of clinical trials</article-title>. <source>Stat Med</source>. <year>1990</year>;<volume>9</volume>:<fpage>65</fpage>–<lpage>72</lpage>.</citation></ref><ref id="bibr10-2168479013486658"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kieser</surname><given-names>M</given-names></name><name><surname>Friede</surname><given-names>T</given-names></name></person-group>. <article-title>Simple procedures for blinded sample size adjustment that do not affect the type I error rate</article-title>. <source>Stat Med</source>. <year>2003</year>;<volume>22</volume>:<fpage>3571</fpage>–<lpage>3581</lpage>.</citation></ref><ref id="bibr11-2168479013486658"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friede</surname><given-names>T</given-names></name><name><surname>Kieser</surname><given-names>M</given-names></name></person-group>. <article-title>Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis</article-title>. <source>Pharm Stat</source>. <year>2011</year>;<volume>10</volume>:<fpage>8</fpage>–<lpage>13</lpage>.</citation></ref><ref id="bibr12-2168479013486658"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friede</surname><given-names>T</given-names></name><name><surname>Kieser</surname><given-names>M</given-names></name></person-group>. <article-title>Sample size recalculation for binary data in internal pilot study designs</article-title>. <source>Pharm Stat</source>. <year>2004</year>;<volume>3</volume>:<fpage>269</fpage>–<lpage>279</lpage>.</citation></ref><ref id="bibr13-2168479013486658"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friede</surname><given-names>T</given-names></name><name><surname>Schmidli</surname><given-names>H</given-names></name></person-group>. <article-title>Blinded sample size reestimation with count data: methods and applications in multiple sclerosis</article-title>. <source>Stat Med</source>. <year>2010</year>;<volume>29</volume>:<fpage>1145</fpage>–<lpage>1156</lpage>.</citation></ref><ref id="bibr14-2168479013486658"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friede</surname><given-names>T</given-names></name><name><surname>Kieser</surname><given-names>M</given-names></name></person-group>. <article-title>Sample size recalculation in internal pilot study designs: a review</article-title>. <source>Biom J</source>. <year>2006</year>;<volume>48</volume>:<fpage>537</fpage>–<lpage>555</lpage>.</citation></ref><ref id="bibr15-2168479013486658"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friede</surname><given-names>T</given-names></name><name><surname>Stammer</surname><given-names>H</given-names></name></person-group>. <article-title>Sample size recalculation in noninferiority trials: a case study in dermatology</article-title>. <source>Drug Inf J</source>. <year>2010</year>;<volume>44</volume>:<fpage>599</fpage>–<lpage>607</lpage>.</citation></ref><ref id="bibr16-2168479013486658"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chuang-Stein</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Gallo</surname><given-names>P</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name></person-group>. <article-title>Sample size reestimation: a review and recommendations</article-title>. <source>Drug Inf J</source>. <year>2006</year>;<volume>40</volume>:<fpage>475</fpage>–<lpage>484</lpage>.</citation></ref><ref id="bibr17-2168479013486658"><label>17</label><citation citation-type="book"><collab collab-type="author">International Conference on Harmonisation</collab>. <source>Topic E9. Note for Guidance on Statistical Principles for Clinical Trials</source>. <publisher-loc>London</publisher-loc>: <publisher-name>EMEA</publisher-name>; <year>1998</year>.</citation></ref><ref id="bibr18-2168479013486658"><label>18</label><citation citation-type="book"><collab collab-type="author">Committee for Medicinal Products for Human Use</collab>. <source>Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned With an Adaptive Design</source>. <publisher-loc>London</publisher-loc>: <publisher-name>EMEA</publisher-name>; <year>2007</year>.</citation></ref><ref id="bibr19-2168479013486658"><label>19</label><citation citation-type="book"><collab collab-type="author">US Food and Drug Administration</collab>. <source>Draft Guidance for Industry. Adaptive Design Clinical Trials for Drugs and Biologics</source>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>US Food &amp; Drug Administration</publisher-name>; <year>2010</year>.</citation></ref><ref id="bibr20-2168479013486658"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>A</given-names></name><name><surname>Carey</surname><given-names>V</given-names></name><name><surname>Schouten</surname><given-names>J</given-names></name><name><surname>Segal</surname><given-names>M</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name></person-group>. <article-title>A parametric family of correlation structures for the analysis of longitudinal data</article-title>. <source>Biometrics</source>. <year>1992</year>;<volume>48</volume>:<fpage>733</fpage>–<lpage>742</lpage>.</citation></ref><ref id="bibr21-2168479013486658"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birkett</surname><given-names>MA</given-names></name><name><surname>Day</surname><given-names>SJ</given-names></name></person-group>. <article-title>Internal pilot studies for estimating sample size</article-title>. <source>Stat Med</source>. <year>1994</year>;<volume>13</volume>:<fpage>2455</fpage>–<lpage>2463</lpage>.</citation></ref><ref id="bibr22-2168479013486658"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mancl</surname><given-names>LA</given-names></name><name><surname>Leroux</surname><given-names>BG</given-names></name></person-group>. <article-title>Efficiency of regression estimates for clustered data</article-title>. <source>Biometrics</source>. <year>1996</year>;<volume>52</volume>:<fpage>500</fpage>–<lpage>511</lpage>.</citation></ref><ref id="bibr23-2168479013486658"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>A</given-names></name><name><surname>Vens</surname><given-names>M</given-names></name></person-group>. <article-title>Generalized estimating equations—notes on the choice of the working correlation matrix</article-title>. <source>Methods Inf Med</source>. <year>2010</year>;<volume>49</volume>:<fpage>421</fpage>–<lpage>425</lpage>.</citation></ref><ref id="bibr24-2168479013486658"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname><given-names>JM</given-names></name><name><surname>Rotnitzki</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>LP</given-names></name></person-group>. <article-title>Analysis of semiparametric regression models for repeated outcomes in the presence of missing data</article-title>. <source>J Am Stat Assoc</source>. <year>1995</year>;<volume>90</volume>:<fpage>106</fpage>–<lpage>121</lpage>.</citation></ref><ref id="bibr25-2168479013486658"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Kronfeld</surname><given-names>K</given-names></name><name><surname>Boewing</surname><given-names>G</given-names></name><etal/></person-group>; <collab collab-type="author">GERAC Migraine Study Group</collab>. <article-title>Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomized controlled clinical trial</article-title>. <source>Lancet Neurol</source>. <year>2006</year>;<volume>5</volume>(<issue>4</issue>):<fpage>310</fpage>–<lpage>316</lpage>.</citation></ref></ref-list></back></article>